Subgroup Analyses from a Phase 3, Open-Label, Randomized Study of Eribulin Mesylate Versus Capecitabine in Pretreated Patients with Advanced or Metastatic Breast Cancer

PURPOSE AND METHODS: Our secondary analyses compared survival with eribulin versus capecitabine in various patient subgroups from a phase 3, open-label, randomized study. Eligible women aged ≥18 years with advanced/metastatic breast cancer and ≤3 prior chemotherapies (≤2 for advanced/metastatic dise...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Breast Cancer (Auckl)
Main Authors: Twelves, Chris, Awada, Ahmad, Cortes, Javier, Yelle, Louise, Velikova, Galina, Olivo, Martin S., Song, James, Dutcus, Corina E., Kaufman, Peter A.
Formato: Artigo
Idioma:Inglês
Publicado em: Libertas Academica 2016
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4927108/
https://ncbi.nlm.nih.gov/pubmed/27398025
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4137/BCBCR.S39615
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados